SCHEMBL19667638

SCHEMBL19667638

CC1CN(C(=O)OC(C)(C)C)Cc2c(OCc3ccccc3)cc(Br)c(F)c21

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TLR9 Q9NR96 4/20 0.41
TLR7 Q9NYK1 2/20 0.41
YAP1 P46937 3/20 0.38
CCNT1 O60563 1/20 0.38
CCNA2 P20248 1/20 0.38
CDK2 P24941 1/20 0.38
CDK9 P50750 1/20 0.38
CCNA1 P78396 1/20 0.38
TACR1 P25103 2/20 0.37
GPR119 Q8TDV5 1/20 0.37
S1PR5 Q9H228 1/20 0.37
KDM1A O60341 4/20 0.36
GLRA1 P23415 1/20 0.36
USP30 Q70CQ3 1/20 0.36
MEN1 O00255 1/20 0.36
ALDH1A1 P00352 1/20 0.36
LMNA P02545 1/20 0.36
MAPT P10636 1/20 0.36
HPGD P15428 1/20 0.36
KMT2A Q03164 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30207830 1.00 TLR9 (0.41) TLR9TLR7YAP1CCNT1CCNA2
SCHEMBL29118112 0.89 KDM1A (0.40) S1PR5KDM1AGLRA1MEN1ALDH1A1
SCHEMBL19679357 0.88 TLR9 (0.41) TLR9TLR7YAP1CCNT1CCNA2
SCHEMBL19667320 0.88 TLR9 (0.41) TLR9TLR7YAP1CCNT1CCNA2
SCHEMBL30207922 0.88 TLR9 (0.41) TLR9TLR7YAP1CCNT1CCNA2
SCHEMBL30207953 0.88 TLR9 (0.41) TLR9TLR7YAP1CCNT1CCNA2
SCHEMBL19667425 0.88 TLR9 (0.41) TLR9TLR7YAP1CCNT1CCNA2
SCHEMBL30207845 0.85 TLR9 (0.42) TLR9TLR7YAP1CCNT1CCNA2
SCHEMBL19667460 0.85 TLR9 (0.42) TLR9TLR7YAP1CCNT1CCNA2
SCHEMBL19667217 0.82 PTGDR2 (0.46) TLR9TLR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3464249-B1 SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS PFIZER (US) 2021-08-11 EP disclosed
EP-3464249-B1 SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS PFIZER (US) 2021-08-11 EP disclosed
US-10709709-B2 Substituted carbonucleoside derivatives useful as anticancer agents PFIZER INC. (US) 2020-07-14 US disclosed
US-20190111060-A1 SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS PFIZER INC. (US) 2019-04-18 US disclosed
US-10220037-B2 Substituted carbonucleoside derivatives useful as anticancer agents PFIZER INC. (US) 2019-03-05 US disclosed
US-20170348313-A1 SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS PFIZER INC. (US) 2017-12-07 US disclosed
US-20170348313-A1 SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS PFIZER INC. (US) 2017-12-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10709709-B2 Substituted carbonucleoside derivatives useful as anticancer agents DUT, NCL, TYMP TLR9 3850/4885TLR7 3752/4885YAP1 4202/4885
US-20170348313-A1 SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS DUT, NCL, TYMP TLR9 3850/4885TLR7 3752/4885YAP1 4202/4885
US-20190111060-A1 SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS DUT, NCL, TYMP TLR9 3850/4885TLR7 3752/4885YAP1 4202/4885
US-10220037-B2 Substituted carbonucleoside derivatives useful as anticancer agents DUT, NCL, TYMP TLR9 3850/4885TLR7 3752/4885YAP1 4202/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.